Patricia Inácio, PhD,  science writer—

Under a new commercialization agreement with Samsung Bioepis, the developer of Epysqli (eculizumab-aagh), Teva Pharmaceuticals will have exclusive marketing rights in the U.S. for the Soliris (eculizumab) biosimilar — an approved treatment for atypical hemolytic uremic syndrome (aHUS). A biosimilar is a biological product that is highly similar to…

Physicians in India described the case of atypical hemolytic uremic syndrome (aHUS) that manifested as loss of vision in one eye in a 30-year-old man. The patient was successfully managed with plasma therapy, because Soliris (eculizumab) was not available. “This is the first described case to our knowledge…

Mutations in the Wilms’ tumor 1 (WT1) gene, known to cause a rare kidney disorder called Denys-Drash syndrome, were found in four children who had symptoms of atypical hemolytic uremic syndrome (aHUS), according to recent case series study. “To our knowledge, this is the first report of a series…

The first case of a patient with both atypical hemolytic uremic syndrome (aHUS) and Brugada syndrome, an irregular heartbeat disorder that increases the risk of sudden death, was described in a report involving a 15-year-old girl in Oman. The researchers noted that “atypical HUS is a variable disease that…

The kidney function of a woman with atypical hemolytic uremic syndrome (aHUS) was completely rescued with Soliris (eculizumab), but only after more than a year of treatment, a case study reports. “This case report supports the hypothesis that kidney pathological [disease] resolution in complement-mediated aHUS requires a long…

The U.S. Food and Drug Administration (FDA) has approved Epysqli (eculizumab-aagh), a biosimilar to Soliris (eculizumab), as an atypical hemolytic uremic syndrome (aHUS) treatment. Epysqli, from Samsung Bioepis, has also been approved to treat people with paroxysmal nocturnal hemoglobinuria (PNH), a rare disease that, like aHUS,…

The American Kidney Fund (AKF) has launched the Rare Kidney Disease Action Network (RKDAN), an initiative to raise awareness and give greater voice to people with rare kidney disorders, including atypical hemolytic uremic syndrome (aHUS). AKF will work along with the more than 60 people already enrolled in…

Early treatment with plasma exchange, or plasmapheresis, followed by the immunosuppressant rituximab helped a 2-year-old girl who was diagnosed with a case of severe atypical hemolytic uremic syndrome (aHUS), a study in India reports. The report showcases how “young children with [aHUS] may present with a severe clinical course…

Researchers in Mexico described the series of events that led to a diagnosis of atypical hemolytic uremic syndrome (aHUS) in a 22-year-old pregnant woman. The case highlights the need for vigilance, as well as prompt diagnosis and treatment, they said. The report, “Pregnancy-associated atypical hemolytic uremic…

At the onset of atypical hemolytic uremic syndrome (aHUS), patients are already showing signs of severe kidney injury, regardless of the specific triggers or disease-related clinical conditions they might also harbor, a registry study has found. Cancer, pregnancy, and acute infections were identified as the most common triggers before…